Fast Track designation meaningfully de-risks development and enhances the probability of earlier approval; traders should monitor upcoming Phase 1 data readouts in H2 2026 as the next major catalyst. Consider positioning ahead of data disclosure, given the high unmet need and lack of targeted therapies in non-G12C KRAS-mutant pancreatic cancer.
Price Chart
Executive Summary
BBOT announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor BBO-11818 for advanced KRAS-mutant pancreatic ductal adenocarcinoma, a significant regulatory milestone that accelerates development for a high-unmet-need cancer indication. The decision follows early clinical evidence of anti-tumor activity, including a confirmed partial response in pancreatic cancer.
Key Facts
- FDA granted Fast Track designation to BBO-11818 for advanced KRAS-mutant pancreatic ductal adenocarcinoma.
- BBO-11818 is a pan-KRAS inhibitor targeting KRASG12D and KRASG12V, beyond just G12C mutations.
- Preliminary data from January 2026 showed a confirmed partial response in pancreatic cancer and tumor reductions across dose levels.
- Phase 1 KONQUER-101 trial is ongoing, with updated data expected in the second half of 2026.
- Fast Track status enables more frequent FDA interactions and potential for accelerated approval.
Financial Impact
Non-dilutive catalyst with potential to increase valuation based on accelerated development timeline and expanded commercial potential in pancreatic cancer.
Risk Factors
- Clinical data remains early-stage; confirmed responses limited to monotherapy in small cohorts.
- Development timelines could slip due to enrollment delays or safety issues.
- Competition from other pan-KRAS or combination therapies may emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277472 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.69 (+45.66%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.69 (−60.18%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.69 (+70.24%) |
Aug 11, 2026 11w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.69 (−71.44%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.69 (−64.13%) |
May 12, 2026 24w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.69 (−66.71%) |
Apr 21, 2026 27w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.69 (−69.67%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.69 (−71.56%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers